|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WASHC2A |
Gene summary for WASHC2A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WASHC2A | Gene ID | 387680 |
| Gene name | WASH complex subunit 2A | |
| Gene Alias | FAM21A | |
| Cytomap | 10q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q641Q2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 387680 | WASHC2A | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.51e-02 | 4.36e-01 | -0.0811 |
| 387680 | WASHC2A | HTA11_78_2000001011 | Human | Colorectum | AD | 6.08e-07 | 5.30e-01 | -0.1088 |
| 387680 | WASHC2A | HTA11_347_2000001011 | Human | Colorectum | AD | 2.26e-11 | 5.65e-01 | -0.1954 |
| 387680 | WASHC2A | HTA11_83_2000001011 | Human | Colorectum | SER | 1.09e-05 | 5.57e-01 | -0.1526 |
| 387680 | WASHC2A | HTA11_696_2000001011 | Human | Colorectum | AD | 2.75e-10 | 3.36e-01 | -0.1464 |
| 387680 | WASHC2A | HTA11_866_2000001011 | Human | Colorectum | AD | 4.56e-06 | 2.60e-01 | -0.1001 |
| 387680 | WASHC2A | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.89e-07 | 5.62e-01 | -0.059 |
| 387680 | WASHC2A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.92e-04 | -2.05e-01 | 0.294 |
| 387680 | WASHC2A | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.62e-04 | -2.05e-01 | 0.3859 |
| 387680 | WASHC2A | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.07e-04 | -2.05e-01 | 0.3005 |
| 387680 | WASHC2A | HCC1 | Human | Liver | HCC | 3.52e-20 | 3.89e+00 | 0.5336 |
| 387680 | WASHC2A | HCC2 | Human | Liver | HCC | 3.33e-33 | 4.71e+00 | 0.5341 |
| 387680 | WASHC2A | HCC5 | Human | Liver | HCC | 3.36e-10 | 2.05e+00 | 0.4932 |
| 387680 | WASHC2A | S014 | Human | Liver | HCC | 2.64e-11 | 4.42e-01 | 0.2254 |
| 387680 | WASHC2A | S015 | Human | Liver | HCC | 1.03e-10 | 3.89e-01 | 0.2375 |
| 387680 | WASHC2A | S016 | Human | Liver | HCC | 1.10e-14 | 4.48e-01 | 0.2243 |
| 387680 | WASHC2A | S027 | Human | Liver | HCC | 5.78e-13 | 5.75e-01 | 0.2446 |
| 387680 | WASHC2A | S028 | Human | Liver | HCC | 1.88e-22 | 6.41e-01 | 0.2503 |
| 387680 | WASHC2A | S029 | Human | Liver | HCC | 1.77e-23 | 8.08e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0016482 | Colorectum | AD | cytosolic transport | 68/3918 | 168/18723 | 6.00e-09 | 3.72e-07 | 68 |
| GO:0042147 | Colorectum | AD | retrograde transport, endosome to Golgi | 37/3918 | 91/18723 | 1.46e-05 | 3.14e-04 | 37 |
| GO:0036010 | Colorectum | AD | protein localization to endosome | 12/3918 | 24/18723 | 1.48e-03 | 1.25e-02 | 12 |
| GO:00161971 | Colorectum | SER | endosomal transport | 61/2897 | 230/18723 | 1.03e-05 | 3.35e-04 | 61 |
| GO:00164821 | Colorectum | SER | cytosolic transport | 46/2897 | 168/18723 | 5.20e-05 | 1.25e-03 | 46 |
| GO:00360101 | Colorectum | SER | protein localization to endosome | 9/2897 | 24/18723 | 7.19e-03 | 4.99e-02 | 9 |
| GO:00161972 | Colorectum | MSS | endosomal transport | 79/3467 | 230/18723 | 7.04e-09 | 4.39e-07 | 79 |
| GO:00164822 | Colorectum | MSS | cytosolic transport | 59/3467 | 168/18723 | 2.29e-07 | 9.79e-06 | 59 |
| GO:00421471 | Colorectum | MSS | retrograde transport, endosome to Golgi | 33/3467 | 91/18723 | 4.78e-05 | 8.71e-04 | 33 |
| GO:00360102 | Colorectum | MSS | protein localization to endosome | 12/3467 | 24/18723 | 4.68e-04 | 5.50e-03 | 12 |
| GO:001619721 | Liver | HCC | endosomal transport | 154/7958 | 230/18723 | 4.74e-14 | 2.95e-12 | 154 |
| GO:001648221 | Liver | HCC | cytosolic transport | 117/7958 | 168/18723 | 8.83e-13 | 4.48e-11 | 117 |
| GO:004214721 | Liver | HCC | retrograde transport, endosome to Golgi | 61/7958 | 91/18723 | 1.94e-06 | 2.68e-05 | 61 |
| GO:00360103 | Liver | HCC | protein localization to endosome | 19/7958 | 24/18723 | 2.80e-04 | 2.02e-03 | 19 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WASHC2A | SNV | Missense_Mutation | novel | c.2669C>T | p.Ser890Phe | p.S890F | Q641Q2 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| WASHC2A | SNV | Missense_Mutation | novel | c.772N>A | p.Gly258Ser | p.G258S | Q641Q2 | protein_coding | deleterious(0.02) | possibly_damaging(0.604) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| WASHC2A | SNV | Missense_Mutation | novel | c.1108N>A | p.Asp370Asn | p.D370N | Q641Q2 | protein_coding | tolerated(0.08) | probably_damaging(0.927) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
| WASHC2A | SNV | Missense_Mutation | novel | c.2149G>A | p.Glu717Lys | p.E717K | Q641Q2 | protein_coding | tolerated(0.09) | possibly_damaging(0.481) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| WASHC2A | SNV | Missense_Mutation | novel | c.2354C>T | p.Ser785Leu | p.S785L | Q641Q2 | protein_coding | deleterious(0.02) | benign(0.311) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
| WASHC2A | SNV | Missense_Mutation | novel | c.880N>A | p.Ala294Thr | p.A294T | Q641Q2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| WASHC2A | insertion | Frame_Shift_Ins | novel | c.413_414insTCTCC | p.Tyr139LeufsTer35 | p.Y139Lfs*35 | Q641Q2 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| WASHC2A | SNV | Missense_Mutation | novel | c.292C>T | p.Arg98Cys | p.R98C | Q641Q2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WASHC2A | SNV | Missense_Mutation | novel | c.1841C>T | p.Ser614Phe | p.S614F | Q641Q2 | protein_coding | deleterious(0) | benign(0.391) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WASHC2A | SNV | Missense_Mutation | novel | c.3058N>G | p.Gln1020Glu | p.Q1020E | Q641Q2 | protein_coding | deleterious(0.02) | possibly_damaging(0.907) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |